New management strategies in ARDS. Immunomodulation.
Acute respiratory distress syndrome is a common condition among the critically ill and is associated with high morbidity and mortality [table: see text] rates. Improved understanding of the underlying inflammatory pathogenetics has encouraged the search for strategies that, by modifying this immune response, can improve outcome for this group of patients. Some agents are obviously anti-inflammatory. Others have been used primarily for other purposes; their immune effects are incidental, but no less important. Although immunomodulatory strategies have been discussed for many years, they now are beginning to show positive results, as in the study using activated protein C. Most patients with ARDS die with ARDS, rather than from ARDS. The approach to treatment must not be lung-limited but must take into account the systemic effects of the inflammatory response. The complex nature of the syndrome makes it likely that no single agent will provide the long-desired cure. Rather, it is probable that an individual patient will require a combination of several agents or different agents at different times during the disease process (Table 1). Mortality rates from ARDS already are beginning to fall with improved nutritional and ventilatory support. Positive results from trials using immunomodulatory agents are being reported, and soon such agents will form part of the routine management of patients with ARDS, further improving the outlook for these patients.
Vincent
Jean-Louis
JL
Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium. jlvincen@ulb.ac.be
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D006801:Humans; D012128:Respiratory Distress Syndrome / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*
D000276:Adjuvants, Immunologic